$9.87
-1.8%ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโmonitor closely.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ICCC โข NASDAQ
| ImmuCell Corporation Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-1M | -2.2M | -5.8M | -2.5M | -78.3K | -1M | -1.3M | -2.3M | -168.1K | 508.4K | 1.2M | -167.2K | 117.4K | 89.5K | -409.5K | -384.7K | -216.5K | -468.6K | 662.1K | 143.5K | |
2.7M | 2.7M | 2.7M | 2.5M | 2.5M | 2.3M | 2.3M | 1.5M | 904.4K | 802.4K | 529.3K | 448.9K | 417.2K | 402.5K | 418.4K | 419.5K | 424.4K | 399.1K | 788.9K | 278.5K | |
0.0 | 0.0 | 0.0 | 0.0 | 31K | -14.6K | 24.7K | 462.3K | -284.8K | 236.3K | 821.5K | -88.6K | 87.2K | 94.4K | -302.5K | -299.2K | -213.3K | -108.1K | 435.2K | -62.1K | |
295.9K | 326K | 368.9K | 266.2K | 144.3K | 253.1K | 313.1K | 344K | 199.8K | 67.4K | 23.2K | 30K | 31.4K | 36K | 38.2K | 29.5K | 94.1K | 55.3K | 0.0 | 0.0 | |
2.5M | -91.8K | 260.8K | 28.8K | 18.6K | -780.4K | 19.4K | -681.4K | -8.4K | 37.5K | -4K | 4.5K | 35.2K | 12.3K | 10.8K | 575.0 | 29.9K | 51.9K | 87.2K | 68.6K | |
(10.7K) | (7.3K) | (0.0) | (4.9K) | (5.1K) | (4.6K) | (3.6K) | (4.2K) | (6.1K) | (123.6K) | (3.1K) | (252.0) | (0.0) | (708.0) | (510.0) | (144.0) | (360.8K) | (147.7K) | (0.0) | (0.0) | |
-2.1M | -406.5K | -2.3M | -1.8M | -1.6M | 532.3K | -1.1M | 302.7K | 532.9K | -2M | 317K | 74.7K | 410.4K | -290.3K | 207.3K | -574.4K | -228.2K | 123.5K | -1.6M | 926.6K | |
2.5M | 357.9K | -4.7M | -1.5M | 954.2K | 1.3M | 233.5K | -373.4K | 1.2M | -323.9K | 2.9M | 302.4K | 1.1M | 344.4K | -37.3K | -808.6K | -109.7K | 53.1K | 349.6K | 1.4M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
(0.0) | -465.7K | -1.9M | -4M | -2.6M | -4.1M | -1.4M | -2M | -17.8M | -3.6M | -2.7M | -1.5M | -597.7K | -275.4K | -243.7K | -116.5K | -459.5K | -410.6K | -1.5M | -1.3M | |
(0.0) | (0.0) | (0.0) | (11K) | (15.3K) | (45.6K) | -8.9K | -14.1K | -8.7K | -368.2K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | -15.3K | -2M | -10.1M | (0.0) | -249K | -5M | -4.5M | -3M | -3.2M | -2.2M | -4.2M | -3.7M | -3.6M | -4.5M | -4.8M | -3.7M | |
0.0 | 0.0 | 0.0 | 0.0 | 996K | 3.4M | 7.7M | 0.0 | 5.7M | 4.5M | 2.5M | 3M | 2.5M | 4.2M | 3.2M | 4.1M | 3.9M | 4.9M | 5.9M | 1.9M | |
-1.2M | 4.5K | 2.5K | 11K | 15.3K | 45.6K | 450K | 250K | 45K | 30.9K | 66.2K | 0.0 | -745K | 1.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4K | |
-1.2M | -461.2K | -1.9M | -4M | -1.6M | -2.6M | -3.4M | -1.8M | -12.3M | -4.4M | -4.6M | -1.5M | -1.3M | (1.7M) | -1.2M | (266.5K) | -215.4K | -45.8K | -481.4K | -3.2M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
349.3K | 4.4M | 18.8K | 0.0 | 4.2M | 0.0 | 8.3M | 0.0 | 3.8M | 8.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6K | 0.0 | 0.0 | -27.2K | 146.3K | |
-1.5M | -1.5M | 1.8M | 1.1M | -368.3K | 2M | -1.4M | 795.3K | 6M | -135.8K | 2.3M | -190.3K | -181.4K | -172.9K | 454.8K | 986.1K | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -65.5K | (0.0) | |
-82.1K | -5K | -62.8K | 11.4K | 14K | -53.1K | 8.3M | 94.3K | 3.8M | -14.8K | 111.8K | 3.1K | 22.1K | 58.1K | 159.8K | -26.5K | 100.7K | 2.0 | 2.8K | 0.0 | |
-1.2M | 2.9M | 1.8M | 1.1M | 3.9M | 1.9M | 6.9M | 889.6K | 9.7M | 8.3M | 2.4M | -187.2K | -159.3K | -114.8K | 614.6K | 965.7K | 100.7K | 2.0 | -24.4K | 146.3K | |
CASH FLOW SUMMARY | ||||||||||||||||||||
48.6K | 2.8M | -4.8M | -4.4M | 3.2M | 656.6K | 3.8M | -1.3M | -1.4M | 3.6M | 723.3K | -1.4M | -403.3K | 1.9M | -617.5K | 423.5K | -224.4K | 7.3K | -156.2K | -1.7M | |
3.8M | 978.7K | 5.8M | 10.2M | 6.9M | 6.3M | 2.5M | 3.8M | 5.2M | 1.6M | 850K | 2.3M | 2.7M | 781.5K | 1.4M | 975.5K | 1.2M | 1.2M | 1.3M | 3.4M | |
3.8M | 3.8M | 978.7K | 5.8M | 10.2M | 6.9M | 6.3M | 2.5M | 3.8M | 5.2M | 1.6M | 850K | 2.3M | 2.7M | 781.5K | 1.4M | 975.5K | 1.2M | 1.2M | 1.7M | |
1.2M | -107.8K | -6.6M | -5.5M | -1.7M | -2.8M | -1.2M | -2.4M | -16.6M | -3.9M | 181K | -1.2M | 501K | 69K | -281.1K | -925.2K | -569.2K | -357.5K | -1.2M | 54.8K |
ICCC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | May 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 14, 2026 | April 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 08, 2026 | April 08, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 18, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 |
Continue your ICCC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.